January 3, 2017
Reston, Va. – Johannes Czernin, MD, has assumed leadership of The Journal of Nuclear Medicine (JNM), the educational flagship publication of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Czernin is a professor of molecular and medical pharmacology and the chief of the Ahmanson Translational Imaging Division at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).
Czernin has taken over leadership of the journal from Dominique Delbeke, MD, PhD, and his official five-year term begins with the January 2017 issue. “I am honored to be entrusted with the JNM editorship and grateful to Dr. Delbeke for her guidance and leadership of a journal that is so highly regarded in the field,” he said. He steps up as editor-in-chief after serving as an associate editor for his two predecessors.
Czernin sees a bright future for nuclear medicine and its contributions to high-quality healthcare. He explains, “During the next decade, nuclear medicine will experience a remarkable renaissance as diagnostic, predictive, and prognostic biomarkers become integrated with novel therapeutic approaches. After all, the dream of precision medicine is unlikely to become a reality without the ability to determine whole-body target expression and inhibition or to provide accurate, early treatment-response assessment.”
Czernin envisions JNM at the center of that renaissance as a vibrant forum for scientific exchange among imaging experts—basic, translational and clinical—where critical and exciting developments will be shared and promoted. Theranostics will be a special emphasis, and other new areas of focus will include hot topics, a state-or-the-art review series, and a featured article.
To accomplish this goal, Czernin has assembled a noteworthy roster of associate editors, including Carolyn J. Anderson, PhD (University of Pittsburgh); Henryk Barthel, MD, PhD (Leipzig University); Frank M. Bengel, MD (Hannover Medical School); Michael M. Graham, PhD, MD (University of Iowa); Jan Grimm, MD, PhD (Memorial Sloan Kettering); Wolf-Dieter Heiss, MD, PhD (Max Planck Institute for Metabolism Research); Gerd Ken Herrmann, MD (University of Essen); E. Edmund Kim, MD (University of California at Irvine); Jason S. Lewis, PhD (Memorial Sloan Kettering); David A. Mankoff, MD, PhD (University of Pennsylvania); Heinrich R. Schelbert, MD, PhD (UCLA); Heiko Schoder, MD (Memorial Sloan Kettering); Piotr J. Slomka, PhD (Cedars-Sinai); H. William Strauss, MD (Memorial Sloan Kettering); David W. Townsend, PhD (A*STAR-NUS Clinical Imaging Research Centre); Wolfgang Weber (Memorial Sloan Kettering); and Harvey Ziessman (Johns Hopkins).
Czernin received his medical degree from the University of Vienna, Austria, in 1983. He was board certified in Internal Medicine in 1989 and began his career at UCLA as a postdoctoral fellow in the lab of Heinrich Schelbert, MD, PhD. In 1996, he was board certified in nuclear medicine and became director of nuclear medicine at the David Geffen School of Medicine at UCLA.
As chief of the Ahmanson Translational Imaging Division, he oversees the Nuclear Medicine Clinic, a clinical imaging research program, a drug and probe development program with a strong underpinning in tumor biology, and a preclinical imaging center. The division’s work is integrated in the department of molecular and medical pharmacology and across other departments, including medicine, surgery, radiology, neurology and pathology. Czernin has authored more than 200 peer-reviewed research papers.
Please visit the SNMMI Media Center for more information about molecular imaging and personalized medicine. To schedule an interview with Johnannes Czernin, MD, please contact Laurie Callahan at (703) 652-6773 or email@example.com. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI’s more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.